
    
      This is a Phase 2a, randomized, double-blind, placebo-controlled, dose-escalation,
      multicenter study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity
      of multiple subcutaneous doses (25, 100, or 200 milligram [mg]) of benralizumab (MEDI-563) in
      adult subjects with asthma.
    
  